EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Patient-derived organoids of lung cancer based on organoids-on-a-chip: enhancing clinical and translational applications

Xiao Zeng, Qiong Ma, Xue-Ke Li, Li-Ting You, Jia Li, Xi Fu, Feng-Ming You, Yi-Feng Ren

Frontiers in Bioengineering and Biotechnology · 26.05.2023 · 11

DOI: 10.3389/fbioe.2023.1205157 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Bioengineering and Biotechnology, online erschienen am 26.05.2023. Verfasst von Xiao Zeng und 7 weiteren Autor:innen. Beteiligte Einrichtung: Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 107 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sichuan Province Science and Technology Support Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lung cancer is one of the most common malignant tumors worldwide, with high morbidity and mortality due to significant individual characteristics and genetic heterogeneity. Personalized treatment is necessary to improve the overall survival rate of the patients. In recent years, the development of patient-derived organoids (PDOs) enables lung cancer diseases to be simulated in the real world, and closely reflects the pathophysiological characteristics of natural tumor occurrence and metastasis, highlighting their great potential in biomedical applications, translational medicine, and personalized treatment. However, the inherent defects of traditional organoids, such as poor stability, the tumor microenvironment with simple components and low throughput, limit their further clinical transformation and applications. In this review, we summarized the developments and applications of lung cancer PDOs and discussed the limitations of traditional PDOs in clinical transformation. Herein, we looked into the future and proposed that organoids-on-a-chip based on microfluidic technology are advantageous for personalized drug screening. In addition, combined with recent advances in lung cancer research, we explored the translational value and future development direction of organoids-on-a-chip in the precision treatment of lung cancer.

Schlagwörter

Stichwörter der Autor:innen

drug screeninglung cancermicrofluidic chiporganoids-on-a-chippatient-derived organoids

Autor:innen und Institutionen

  • Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
  • Cancer Institute, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
  • Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Förderung

  • Sichuan Province Science and Technology Support Program

Zitieren

APA

Zeng, X., Ma, Q., Li, X. K., You, L. T., Li, J., Fu, X., You, F. M., & Ren, Y. F. (2023). Patient-derived organoids of lung cancer based on organoids-on-a-chip: enhancing clinical and translational applications. Frontiers in Bioengineering and Biotechnology, 11. https://doi.org/10.3389/fbioe.2023.1205157

Vancouver

Zeng X, Ma Q, Li XK, You LT, Li J, Fu X, et al. Patient-derived organoids of lung cancer based on organoids-on-a-chip: enhancing clinical and translational applications. Frontiers in Bioengineering and Biotechnology. 2023;11. doi:10.3389/fbioe.2023.1205157

BibTeX
@article{Zeng2023,
  author = {Zeng, Xiao and Ma, Qiong and Li, Xue-Ke and You, Li-Ting and Li, Jia and Fu, Xi and You, Feng-Ming and Ren, Yi-Feng},
  title = {Patient-derived organoids of lung cancer based on organoids-on-a-chip: enhancing clinical and translational applications},
  journal = {Frontiers in Bioengineering and Biotechnology},
  year = {2023},
  volume = {11},
  doi = {10.3389/fbioe.2023.1205157}
}
Kostenlos starten →